Ailomics Therapeutics completed angel round financing

Ailomics Therapeutics announced that it raised tens of millions of RMB in its angel round led by Qiming Venture Partners. The firm plans to use the fresh funds to build the core technology platform and advance its R&D pipeline.

Founded in July 2022, Ailomics Therapeutics is a pharmaceutical R&D startup with a pioneering computational and experimental platform to discover novel targets and develop efficacious therapeutics for the diseases of significant unmet medical needs. The company leverages patients-derived omics data (including scRNA-seq and spatial transcriptomics) and AI-augmented bioinformatics analytics such as Deep Learning to deeply understand disease biology and identify the targets that drive disease progressions for the R&D of First-in-class medicine.

Dr. Kan Chen, Partner of Qiming Venture Partners, said, “Qiming has always focused on innovative companies in biomedicines. With leading digitalization and AI technologies to decode complex disease biology, Ailomics Therapeutics is the pioneer of a new paradigm in new medicine R&D. The founding management team has extensive experience in computational biology, experimental biology and corporate management. Given the huge global unmet medical needs in immune diseases and oncology, we look forward to Ailomics Therapeutics bringing new hopes to patients soon.”

About Ailomics Therapeutics

Ailomics Therapeutics is a pharmaceutical R&D startup with a pioneering computational and experimental platform to discover novel targets and develop efficacious therapeutics for the diseases of significant unmet medical needs. Ailomics Therapeutics leverages patients-derived omics data and AI-augmented bioinformatics analytics to deeply understand disease biology and identify the targets that drive disease progressions. Learning from human disease biology, Ailomics Therapeutics develops high-translatability disease models to screen for and optimize functional molecules for therapeutic interventions. The human disease biology insights also enable Ailomics Therapeutics to discover high-precision biomarkers for patient stratification in clinical trials.